Cart
sales@molnova.com
RNase L-IN-2
CAS No. 357618-26-9
RNase L-IN-2( 5-(3-hydroxyphenyl)-8-thia-4,6-diazatricyclo[7.4.0.0,2,7]trideca-1(9),2(7),5-trien-3-one )
Catalog No. M22237 CAS No. 357618-26-9
RNase L-IN-2 is an activator of RNase L with EC50 of 22 uM; shows broad-spectrum antiviral activity against diverse types of RNA viruses, including the human pathogen human parainfluenza virus type 3, with no cytotoxic at the effective concentrations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 256 | In Stock |
|
| 5MG | 278 | In Stock |
|
| 10MG | 417 | In Stock |
|
| 25MG | 661 | In Stock |
|
| 50MG | 920 | In Stock |
|
| 100MG | 1237 | In Stock |
|
| 200MG | 1655 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRNase L-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionRNase L-IN-2 is an activator of RNase L with EC50 of 22 uM; shows broad-spectrum antiviral activity against diverse types of RNA viruses, including the human pathogen human parainfluenza virus type 3, with no cytotoxic at the effective concentrations.
-
DescriptionRNase L-IN-2 is an activator of RNase L with EC50 of 22 uM; shows broad-spectrum antiviral activity against diverse types of RNA viruses, including the human pathogen human parainfluenza virus type 3, with no cytotoxic at the effective concentrations.
-
In Vitro——
-
In Vivo——
-
Synonyms5-(3-hydroxyphenyl)-8-thia-4,6-diazatricyclo[7.4.0.0,2,7]trideca-1(9),2(7),5-trien-3-one
-
PathwayOthers
-
TargetOther Targets
-
RecptorRNase L
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number357618-26-9
-
Formula Weight298.36
-
Molecular FormulaC16H14N2O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOc1cccc(c1)c4nc3[s]c2CCCCc2c3c(=O)n4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
BLU2864
BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor with an IC50 of 0.3 nM, exhibiting anti-tumor activity and potential applications in cancer and polycystic kidney disease research .
-
Letolizumab
Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.
-
GSK199
GSK199 is a selective PAD4 inhibitor(IC50 of 200 nM in the absence of calcium).
